theMednetRegister

Hepatology   

Questions discussed in this category

Is there a role for use of GLP-1/GIP receptor agonists in the management of substance use disorders, whether or not they meet other inclusion criteria for their use?
2 Answers available
Can fatty liver disease present with elevations in alkaline phosphatase without other liver enzyme elevations (AST and ALT)?
1 Answer available
How do you approach the evaluation of a living donor liver transplant candidate?
What kind of patient would be an ideal recipient of such an organ?
1 Answer available
What patient clinical factors do you find most impact a patient's "beta-blocker window" and their ability to maintain and tolerate beta-blocker therapy?
1 Answer available
When would you choose to measure a patient's spleen stiffness?
What are you looking for that would impact your management of a patient?
2 Answers available
How do you counsel patients on the use of marginal organs and/or high risk donors who are on the liver transplant wait list?
1 Answer available
How do you manage liver enzyme elevations in patients with PBC after starting elanifibranor?
1 Answer available
How does presence of clinically significant portal hypertension change patient prognosis in MASLD?
1 Answer available
How do you approach risk of development of PTLD in liver transplant recipients with positive EBV antibodies and/or viral loads?
1 Answer available
What management considerations do you keep in mind in the management of pregnant patients with autoimmune liver disease?
1 Answer available
Would you consider long term avatrombopag use in patients with cirrhosis requiring higher platelet counts for medical therapy?
For example, someone needing a higher platelet count for dual antiplatelet agent use after coronary stent placement.
1 Answer available
All things being equal, what patient factors are you looking at in the selection of TAF or TDF in the management of hepatitis B?
1 Answer available
What pre-transplant patient factors impact surveillance intervals and methods after liver transplant for HCC?
1 Answer available
What clinical evidence do you find most favorable of a positive response post-liver transplant for patients with portopulmonary hypertension?
1 Answer available
Would you recommend radiation or chemoradiation in a patient with cholangiocarcinoma s/p surgery and adjuvant treatment with single hepatic metastasis 3 years later?
Patient with extrahepatic cholangiocarcinoma s/p Whipple in 2021 with negative margins and no positive nodes followed by adjuvant chemo with subsequen...
1 Answer available
Would you ever consider using durvalumab/tremelimumab in second line after progression on atezolizumab and bevacizumab in advanced HCC?
3 Answers available
How do you rule out spontaneous bacterial peritonitis in a patient with minimal ascites that is not amenable to paracentesis?
1 Answer available
How do you approach dosing beta blockers for variceal prophylaxis when the standard dose doesn’t achieve the target heart rate?"
1 Answer available
If you do not have easy access to Fibroscan, what do you recommend for non-invasive tests to determine if a MASLD patient has clinically significant portal hypertension and risk stratify them?
1 Answer available
How do you manage oxaliplatin-induced splenomegaly?
1 Answer available
What clinical scenario would you favor NOT using terlipressin for the management of HRS if there were no notable contraindications for its initiation?
1 Answer available
How do you manage fatty liver disease in patients on olanzapine who are reluctant to change meds?
I have several forensic patients who have elevated LFTs and fatty liver on ultrasound, at least in part due to long-term olanzapine use. They are all ...
2 Answers available
What is your approach to the management of anti-pruritic therapies in patients with cholestatic liver disease?
Any management considerations with respect to disease etiology?
1 Answer available
What is your approach to the management of post-TIPS hepatic encephalopathy?
1 Answer available
How much do you factor in a patient's frailty in selection for transplant if the underlying driver for their debility is their underlying liver disease itself?
1 Answer available
How do you approach a patient who has incidentally found liver and renal cysts?
1 Answer available
Do you find there is any benefit to giving N-acetyl-cysteine in non-acetaminophen related acute liver failure?
1 Answer available
When would you decide to pursue plasma exchange in a patient in acute liver failure due to sinusoidal obstruction syndrome?
1 Answer available
When would you consider quantification of hepatitis B surface antigen as part of the treatment decision making process?
1 Answer available
Do you avoid peritoneal dialysis in cirrhotic patients with ascites?
3 Answers available
Do you obtain liver biopsy to confirm the diagnosis of cirrhosis if cirrhotic liver morphology is noted on imaging?
2 Answers available
What is your approach to managing concurrent severe SIADH and large-volume malignant ascites when aggressive volume removal appears to exacerbate both symptoms and hyponatremia?
For example, would you consider alternatives to paracentesis (Denver shunt placement, CART therapy, or permanent tunneled catheters) that might better...
1 Answer available
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
2 Answers available
How do you determine whether to limit volume removal during therapeutic paracentesis in a patient without acute or chronic kidney disease?
1 Answer available
How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?
Given the improvement in liver function, what factors should be considered before reinitiating immunotherapy?"
4 Answers available
Is there benefit to aggressively treating hemochromatosis in a patient who has already progressed to cirrhosis at the time of diagnosis?
1 Answer available
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
1 Answer available
How would you manage a patient with well-controlled HIV on Biktarvy, who is interested in switching to injectable HAART but also has a history of a prior Hepatitis B Infection?
2 Answers available


Papers discussed in this category

The New England journal of medicine, 1987-03-05
Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV.
Hepatology (Baltimore, Md.), 2018 Apr
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020 Dec 31
Global Burden of Hepatitis B Infection in People Living With Human Immunodeficiency Virus: A Systematic Review and Meta-analysis.
Journal of viral hepatitis, 2019 Dec 22
Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis.
Topics in antiviral medicine, 2023 Mar 31
Chronic hepatitis B and HIV coinfection.
Journal of acquired immune deficiency syndromes (1999), 2023 Oct 01
Brief Report: Hepatitis B Infection or Reactivation After Switch to 2-Drug Antiretroviral Therapy: A Case Series, Literature Review, and Management Discussion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Mar 19
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
Hepatology (Baltimore, Md.), 2023 May 22
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
Hepatology research : the official journal of the Japan Society of Hepatology, 2025 Jan 15
Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma.
Investigational new drugs, 2024 Aug 30
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.
International journal of molecular sciences, 2022 Mar 13
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.
Archives of internal medicine, 2006 Feb 13
Screening for hemochromatosis in asymptomatic subjects with or without a family history.
Cancer chemotherapy and pharmacology, 2019 Aug 23
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
Gastroenterology, 2009-09
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure.
European journal of endocrinology, 2023 Aug 02
Effect of protein supplementation on plasma sodium levels in the syndrome of inappropriate antidiuresis: a monocentric, open-label, proof-of-concept study-the TREASURE study.
JAMA oncology, 2017-04-01
Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2018-05
Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.
Transplant international : official journal of the European Society for Organ Transplantation, 2021 Nov 22
The RETREAT score provides valid predictions regarding hepatocellular carcinoma recurrence after liver transplantation.
Drug and alcohol dependence, 2024 Sep 07
Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.
JAMA psychiatry, 2025 Apr 01
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.
Gastroenterology, 2018 May 17
Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
The New England journal of medicine, 2012 Aug 23
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
Medicine, 2016 Jan
Peritoneal Dialysis is Associated With A Better Survival in Cirrhotic Patients With Chronic Kidney Disease.
Clinical nephrology, 2011 Oct
Outcome of peritoneal dialysis in cirrhotic patients with end-stage renal disease: a 24-years' experience in Taiwan.
The American journal of medicine, 1992 Jul
Peritoneal dialysis in end-stage renal disease patients with preexisting chronic liver disease and ascites.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002 Jul
Outcome of peritoneal dialysis in cirrhotic patients with chronic renal failure.
The New England journal of medicine, 2024 Jul 25
Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-05-20
Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.
Hepatology (Baltimore, Md.), 2023 Oct 23
AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis.

Related Topics

Copyright © 2025 theMednet
All Rights Reserved.